Improved therapy for clear cell renal cell carcinoma: beta-hydroxybutyrate and quercetin target hypoxia-induced angiogenesis and multidrug resistance.
Nima MohammadipoorRaika NaiebiSeyed Amirhossein MazhariFateme AmooeiMarzieh OwrangSahar DastghaibMesbah ShamsMohammad Hassan MalekiSanaz DastghaibPublished in: Molecular biology reports (2024)
This study highlights the promising potential of a combination therapy involving BHB and QCT in mitigating angiogenesis and MDR4 expression in hypoxia-induced ccRCC cells. These findings support further investigation into the underlying mechanisms and warrant clinical studies to evaluate the therapeutic value of this combined treatment for ccRCC patients. This research provides new insights into addressing the challenges posed by angiogenesis and drug resistance in ccRCC.
Keyphrases
- combination therapy
- endothelial cells
- vascular endothelial growth factor
- end stage renal disease
- ejection fraction
- chronic kidney disease
- induced apoptosis
- newly diagnosed
- wound healing
- multidrug resistant
- prognostic factors
- cell proliferation
- binding protein
- patient reported outcomes
- human health
- replacement therapy
- smoking cessation
- patient reported